GSK agrees £1.6 billion acquisition of cough drug specialist
- All-cash acquisition of BELLUS Health at 103% premium- Deal expected to be earnings accretive from 2027- Potential blockbuster sales opportunity Pharma company GSK (GSK) has agreed to buy Canadian cough drug company BELLUS Health (BLU:NASDAQ) for $14.75 per share in cash, representing a 103% premium to the last closing price.The company said the roughly £1.6 billion transaction is expected to c